ReviewContinuum (Minneapolis, Minn.)2016
Alzheimer Disease.
Review in Continuum (Minneapolis, Minn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Task-based fMRI brain activation in mild cognitive impairment and Alzheimer's disease: an ALE meta-analysis.GeroScience · 2026Pooled it
- Grey-Matter Structure Markers of Alzheimer's Disease, Alzheimer's Conversion, Functioning and Cognition: A Meta-Analysis Across 11 Cohorts.Human brain mapping · 2025Pooled it
- Virtual Reality-Based Cognitive Stimulation on People with Mild to Moderate Dementia due to Alzheimer's Disease: A Pilot Randomized Controlled Trial.International journal of environmental research and public health · 2021Trial
- The Effect of Caregiver Burden on Healthy Lifestyle Behaviours of People Caring for Patients With Alzheimer's Disease: A Cross-Sectional Study.Scandinavian journal of caring sciences · 2026Article
- Article
- Rewiring mTOR signaling in Alzheimer's disease: emerging mTOR modulators beyond oncology.Bioscience reports · 2026Review
- Hypolipidemics reduce the rate of Alzheimer's disease development and dementia progression: A cohort study linked with genetic and neuropathological analyses.The journal of prevention of Alzheimer's disease · 2026Article
- Usefulness ofInternational journal of molecular sciences · 2026Article
- Utility of Self-Rated vs. Informant-Rated Ascertain Dementia-8 for Detection of Early Cognitive Impairment: Experience of a "Real-World" Memory Clinic.Annals of geriatric medicine and research · 2026Article
- A machine learning-enabled blood transcriptomic signature for digital diagnosis and subtyping of Alzheimer's disease.NPJ digital medicine · 2026Article
- Current Perspectives on Oxytocin and Alzheimer's Disease-Related Symptoms.Current Alzheimer research · 2026Review
- Exploring the role of multi-pathogen infections in Alzheimer's disease: A case-control study.Virulence · 2025Article
- Targeting Amyloid Toxicity: Novel Cholinesterase Inhibitors Protect Hippocampal Cells from Amyloid Peptide-Derived Death.Neurochemical research · 2025Article
- Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Sleep and Risk of Multiple Sclerosis: Bridging the Gap Between Inflammation and Neurodegeneration via Glymphatic Failure.Brain sciences · 2025Review
- GPR43 regulates mitochondrial apoptosis through the cyclophilin D pathway in Alzheimer's disease.Molecular medicine (Cambridge, Mass.) · 2025Article
- The dynamics of cognitive decline toward Alzheimer's disease progression: Results from ADSP-PHC's harmonized cognitive composites.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Excess Wnt in neurological disease.The Biochemical journal · 2025Review
- Evaluation of machine learning models for the prediction of Alzheimer's: In search of the best performance.Brain, behavior, & immunity - health · 2025Article
- Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.Journal of cellular and molecular medicine · 2025Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewThis article discusses the recent advances in the diagnosis and treatment of Alzheimer disease (AD). RECENT
findingsIn recent years, significant advances have been made in the fields of genetics, neuroimaging, clinical diagnosis, and staging of AD. One of the most important recent advances in AD is our ability to visualize amyloid pathology in the living human brain. The newly revised criteria for diagnosis of AD dementia embrace the use for biomarkers as supportive evidence for the underlying pathology. Guidelines for the responsible use of amyloid positron emission tomography (PET) have been developed, and the clinical and economic implications of amyloid PET imaging are actively being explored. SUMMARY: Our improved understanding of the clinical onset, progression, neuroimaging, pathologic features, genetics, and other risk factors for AD impacts the approaches to clinical diagnosis and future therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.